Polymorphism of the SRD5A2 gene and the risk of prostate cancer

Dušenka,Róbert; Tomaškin,Roman; Kliment,Ján; Dobrota,Dušan; Dušenková,Svetlana; Vilčková,Marta; Sivoňová,Monika  Kmeť'ová

doi:10.3892/mmr.2014.2621

Polymorphism of the SRD5A2 gene and the risk of prostate cancer

Authors:
- Róbert Dušenka
- Roman Tomaškin
- Ján Kliment
- Dušan Dobrota
- Svetlana Dušenková
- Marta Vilčková
- Monika Kmeť'ová Sivoňová
View Affiliations

Affiliations: Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin 03601, Slovakia, Department of Urology, Jessenius Faculty of Medicine and UHM, Comenius University in Bratislava, Martin 03601, Slovakia
Published online on: October 10, 2014 https://doi.org/10.3892/mmr.2014.2621
Pages: 3151-3156

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Androgens are actively involved in the development of the prostate gland and appear to be essential for prostate carcinogenesis. The product of the SRD5A2 gene, membrane‑bound steroid 5‑α‑reductase, type II enzyme, is key in testosterone metabolism. The present study explored the association between the SRD5A2 V89L gene polymorphism and the risk of developing prostate cancer. The study cohort consisted of 456 male Slovak patients, including 260 cases with histologically confirmed prostate cancer and 196 age‑matched controls without any clinically suspected infections of the prostate. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to detect the SRD5A2 polymorphism on codon 89. Odds ratios (ORs) with corresponding 95% confidence intervals (95% CIs) for different allele variants were calculated in order to determine the association between the SRD5A2 V89L gene polymorphism and prostate cancer. The distribution of V89L variants in the control group was consistent with the Hardy‑Weinberg equilibrium (χ2 test, P=0.266) with a significant deviation in the case group (χ2 test, P=0.04). However, no association between the SRD5A2 polymorphism and an increased risk of developing prostate cancer was identified. When the wild type VV variant was used as a reference, the ORs for different allele variants ranged from 1.11 (95% CI 0.66‑1.87, P=0.70) for the LL genotype to 0.99 (95% CI 0.68‑1.46, P=0.99) for the LL + VL genotypes. No particular allele variant was identified to exhibit an increased capacity to promote the development of highly aggressive prostate cancer (Gleason ≥7) or induce carcinogenesis at an earlier onset (<65 years of age). It was confirmed that in the population studied, the SRD5A2 V89L polymorphism was not associated with the risk of prostate cancer and SRD5A2 was not shown to be a key gene involved in prostate cancer development. Published data indicate that a combination of multiple genetic changes are required for prostate cancer development, rather than a single gene change. Therefore, it was hypothesized that high-throughput genotyping may be more effective than single nucleotide polymorphism detection.

View Figures

View References

1	Grönberg H: Prostate cancer epidemiology. Lancet. 361:859–864. 2003.PubMed/NCBI
2	Ondrušová M and Ondruš D: The occurence and mortality from prostate cancer in Slovakia and abroad. Onkológia (Bratisl.). 4:272–274. 2009.(In Slovak).
3	Plesko I, Obsitníkova A, Cuninkova M, Tomasek L, Stefanakova D and Kubik A: Increasing occurrence of urological cancers in Slovakia. Neoplasma. 51:248–254. 2004.PubMed/NCBI
4	Khan N, Afaq F and Mukhtar H: Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett. 293:133–143. 2010. View Article : Google Scholar : PubMed/NCBI
5	Stein QP and Flanagan JD: Genetic and familial factors influencing breast, colon, prostate and lung cancers. S D Med. 16–22. 2010.PubMed/NCBI
6	Sánchez-Visconti G, Herrero L, Rabadán M, Pereira I and Ruiz-Torres A: Ageing and prostate: age-related changes in androgen receptors of epithelial cells from benign hypertrophic glands compared with cancer. Mech Ageing Dev. 82:19–29. 1995.PubMed/NCBI
7	Brawley OW, Jani AB and Master V: Prostate cancer and race. Curr Probl Cancer. 31:211–225. 2007. View Article : Google Scholar : PubMed/NCBI
8	Sivonova MK, Dobrota D, Matakova T, Dusenka R, Grobarcikova S, et al: Microsomal epoxide hydrolase polymorphisms, cigarette smoking and prostate cancer risk in the Slovak population. Neoplasma. 59:79–84. 2012. View Article : Google Scholar : PubMed/NCBI
9	Imamoto T, Suzuki H, Utsumi T, Endo T, Takano M, et al: Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol. 5:1005–1013. 2009. View Article : Google Scholar
10	Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
11	Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, et al: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer. 48:189–193. 1991.PubMed/NCBI
12	Li X, Huang Y, Fu X, Chen C, Zhang D, et al: Meta-analysis of three polymorphisms in the steroid-5-α-reductase, α polypeptide 2 gene (SRD5A2) and risk of prostate cancer. Mutagenesis. 26:371–383. 2011.PubMed/NCBI
13	Wilbert DM, Griffin JE and Wilson JD: Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab. 56:113–120. 1983. View Article : Google Scholar : PubMed/NCBI
14	Coffey DS: The Molecular Biology of the Prostate. Prostate Diseases. Lepor H and Lawson RK: Saunders; Philadelphia, PA: pp. 28–56. 1993
15	Ross RK, Bernstein L, Lobo RA, Shimizu FZ, Stanczyk FZ, et al: 5-α-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 339:887–889. 1992.
16	Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, et al: Serum androgens and sex-hormone binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 4:735–741. 1995.
17	Ntais C, Polycarpou A and Ioannidis JP: SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 12:618–624. 2003.PubMed/NCBI
18	Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, et al: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
19	Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC and Ross RK: Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 55:3973–3975. 1995.PubMed/NCBI
20	Scariano JK, Treat E, Alba F, Nelson H, Ness SA and Smith AY: The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate. 68:1798–1805. 2008. View Article : Google Scholar : PubMed/NCBI
21	Boger-Megiddo I, Weiss NS, Barnett MJ, Goodman GE and Chen CH: V89L polymorphisms of the 5α-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 17:286–291. 2008.
22	Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, et al: Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemol Biomarkers Prev. 10:1077–1082. 2001.PubMed/NCBI
23	Makridakis NM, di Salle E and Reichardt JK: Biochemical and pharmacogenetic dissection of human steroid 5a-reductase type II. Pharmacogenetics. 10:407–413. 2000. View Article : Google Scholar : PubMed/NCBI
24	Allen NE, Forrest MS and Key TJ: The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev. 10:185–189. 2001.
25	Febbo PG, Kantoff PW, Platz EA, et al: The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res. 59:5878–5881. 1999.
26	Giwercman YL, Abrahamsoon PA, Giwercman A, Gadaleanu V and Ahlgren G: The 5α-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol. 48:679–685. 2005.
27	Berndt SI, Chatterjee N, Huang WY, et al: Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 16:165–168. 2007. View Article : Google Scholar : PubMed/NCBI
28	Li J, Coates RJ, Gwinn M, Khoury MJ, et al: Steroid 5-α-reductase Type 2 (SRD5A2) gene polymorphisms and risk of prostate cancer: a HuGE review. Am J Epidemiol. 171:1–13. 2010.
29	Schatzl G, Madersbacher S, Gsur A, et al: Association of polymorphisms within androgen receptor, 5α-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate. 52:130–138. 2002.
30	Wang CH, Tao W, Chen Q, Hu H, Wen XY, et al: SRD5A2 V89L polymorphism and prostate cancer risk: Meta-analysis. The Prostate. 70:170–178. 2010.PubMed/NCBI
31	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242. 2005. View Article : Google Scholar : PubMed/NCBI
32	Deantoni EP: Age-specific reference ranges for PSA in the detection of prostate cancer. Oncology (Williston Park). 11:475–482. 485–486. 1997.PubMed/NCBI
33	Ausubel F, Brent R, Kingston R, Moore D, Seidman JG, Smith J and Struhl K: Short Protocols in Molecular Biology. 3rd edition. (Unit 21)John Wiley & Sons; New York, NY: pp. 2–3. 1995
34	Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, et al: Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. The Prostate. 59:69–76. 2004. View Article : Google Scholar : PubMed/NCBI
35	Lunn RM, Bell DA, Mohler JL and Taylor JA: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis. 20:1727–1731. 1999. View Article : Google Scholar : PubMed/NCBI
36	Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, et al: 5a-reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. Lancet. 339:887–889. 1992. View Article : Google Scholar : PubMed/NCBI
37	Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, et al: A prevalent missense substitution that modulates activity of prostatic steroid 5a-reductase. Cancer Res. 57:1020–1022. 1997.PubMed/NCBI
38	Zeigler-Johnson CM, Walker AH, Mancke B, et al: Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered. 54:13–21. 2002. View Article : Google Scholar : PubMed/NCBI
39	Jiang J, Tang NL, Ohlsson C, Eriksson AL, Vandenput L, et al: Association of SRD5A2 variants and serum androstane-3α, 17beta-diol glucuronide concentration in Chinese elderly men. Clin Chem. 56:1742–1749. 2010.PubMed/NCBI
40	Hayes VM, Severi G, Padilla EJD and Morris HA: 5α-reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer. 120:776–780. 2006.
41	Allen NE, Forrest MS and Key TJ: The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev. 10:185–189. 2001.
42	Forrest MS, Edwards SM, Houlston R, Kote-Jarai Z, Key T, et al: Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer and Prostatic Diseases. 8:95–102. 2005. View Article : Google Scholar : PubMed/NCBI
43	Allen NE, Reichardt JK, Nguyen H and Key TJ: Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol Biomarkers Prev. 12:578–81. 2003.PubMed/NCBI